Neoadjuvant PD ‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
| العنوان: | Neoadjuvant |
|---|---|
| المؤلفون: | Yuan Feng, Wei Sun, Jie Zhang, Yang Wang, Jinfeng Chen, Xinying Liu, Liang Wang, Shaolei Li, Chao Lv, Fangliang Lu, Jianzhi Zhang, Yang Hong, Shanshan Xiao, Tao Wang, Raymond Jiao, Ziping Wang, Liping Qi, Nan Li, Yue Yang, Dongmei Lin, Jian Fang |
| المصدر: | Thoracic Cancer Thoracic Cancer, Vol 13, Iss 3, Pp 442-452 (2022) |
| بيانات النشر: | Wiley, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Pulmonary and Respiratory Medicine, Lung Neoplasms, major pathological response, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Original Articles, General Medicine, B7-H1 Antigen, Neoadjuvant Therapy, Oncology, neoadjuvant anti‐PD‐1 antibody with chemotherapy, Carcinoma, Squamous Cell, Humans, Original Article, Immune Checkpoint Inhibitors, Lung, squamous cell non‐small‐cell lung cancer, RC254-282 |
| الوصف: | Background A single‐agent of anti programmed cell death 1/programmed cell death ligand 1 (anti‐PD‐1/PD‐L1) therapy has been explored for resectable lung cancer before surgery. However, the effectiveness and safety of neoadjuvant programmed cell death 1 (PD‐1) blockade combined with chemotherapy have not been published. Methods Twenty‐one consecutive patients with potentially resectable squamous cell carcinoma of the lung who received neoadjuvant therapy followed by surgery in Beijing Cancer Hospital were included in this study. Eight patients received two cycles of neoadjuvant platinum‐based doublet chemotherapy combined with anti‐programmed cell death 1 (anti‐PD‐1) therapy, while 13 patients received two cycles of neoadjuvant platinum‐based doublet chemotherapy only. Chest computed tomography was repeated before neoadjuvant treatment and surgery. Adverse events were monitored. The major pathological response (MPR) rate was determined after surgery. Selected specimens were sent for immunohistochemical and multiplex immunofluorescence analyses, and T‐cell receptor DNA sequencing. Results Compared with neoadjuvant chemotherapy alone, the combination of PD‐1 blockade and chemotherapy increased the pathological complete response rate (37.5% vs. 7.69%) and MPR rate (50% vs. 38.46%). The pathological and radiological evaluations are not consistent. No unknown adverse effects were reported for all the patients. More tumor infiltrating lymphocytes were observed in patients who received PD‐1 blockade. No unknown pathological features associated with PD‐1 blockade were found. Immune suppression in the peritumoral spaces around the residual tumor cells was observed. The amino acid sequences of the T‐cell receptors are not significantly shared among the patients. Conclusions The combination of neoadjuvant chemotherapy and PD‐1 blockade is safe and feasible, and might indicate an increased MPR and pathological complete response rate. More investigations are needed for the best combination of the neoadjuvant therapy. Twenty‐one patients with squamous cell carcinoma of the lung were included in this study. Eight patients received two cycles of neoadjuvant platinum‐based doublet chemotherapy combine with anti‐PD‐1 therapy (the IM group), while 13 patients received two cycles of neoadjuvant platinum‐based doublet chemotherapy only (the C group). The combination of PD‐1 blockade and chemotherapy increased the pathological complete response rate (37.5% vs. 7.69%) and major pathological response rate (50% vs. 38.46%). |
| تدمد: | 1759-7714 1759-7706 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0063015f807154b3733ee39a6e4dcd14Test https://doi.org/10.1111/1759-7714.14280Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....0063015f807154b3733ee39a6e4dcd14 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17597714 17597706 |
|---|